Anti Hiv Drugs Market Size Projected to Reach $55.24 billion by 2034 | 6.2%

According to Straits Research the global anti-HIV drugs market size was valued at $32.15 billion in 2025 and is expected to grow from $34.14 billion in 2026 to $55.24 billion by 2034, registering a CAGR of 6.2% during the forecast period 2026–2034.

Human Immunodeficiency Virus (HIV) is a chronic and life-threatening infectious disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus that attacks immune cells known as CD-4 cells, further lowering the immunity. Rising prevalence of HIV is prompting the need for effective anti-HIV drugs.

Anti-HIV drugs help in preventing the multiplication of the HIV virus, thereby reducing the risk of transmission. Currently, HIV is treated using drugs belonging to classes such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs). Some of the prominent drugs available in the market include Truvada, Atripla, Stribild, and Prezista/Prezcobix. The anti-HIV drug market’s most prominent driver is the rising government initiative to awareness regarding the causes, symptoms, and treatments of HIV. Additionally, the introduction of cost-effective generic drugs drives the market growth.

Key Highlights

• The anti-HIV market was valued at $32.15 billion in 2025 and is expected to grow with a CAGR of 6.2%. Increasing number of pipeline products to address the growing prevalence of HIV drive the market growth.
• The multi-class combination drugs segment held the largest market share in 2018 due to their efficacy in inhibiting multiple aspects of HIV transmission, such as incoming viral load, virus-infected cells, and cells susceptible to HIV infection.
• The hospital pharmacies segment held the highest market share in 2018 owing to increasing awareness about HIV drugs and improving healthcare infrastructure in both developed and developing countries.

Market Segments

1. By Medication Class
   1. Multi-class combination drugs
   2. Nucleoside reverse transcriptase inhibitors (NRTIs)
   3. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
   4. HIV integrase strand transfer inhibitors
2. By Distribution Channel
   1. Hospital pharmacies
   2. Retail pharmacies
   3. E-commerce